← All trials
NCT05597722
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Nov 15, 2023
- Completion date
- Nov 30, 2023
- First posted
- Oct 28, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghOverall official - principal investigator
- University of PittsburghSponsor investigator
- The Beckwith InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.